Prospect: information for the patient

Agomelatina Stada 25 mg film-coated tablets EFG

Read this prospect carefully before starting to take this medicine, as it contains important information for you.

-Keep this prospect, as you may need to read it again.

-If you have any doubts, consult your doctor or pharmacist.

-This medicine has been prescribed only to you and should not be given to others, even if they have the same symptoms as you, as it may harm them.

-If you experience any adverse effects, consult your doctor or pharmacist even if they do not appear in this prospect. See section 4.

1.What is Agomelatina Stada and for what it is used

2.What you need to know before starting to take Agomelatina Stada

3.How to take Agomelatina Stada

4.Possible adverse effects

5Storage of Agomelatina Stada

6.Contents of the package and additional information

This medicationcontains the active ingredient agomelatina. Agomelatina belongs to a group of medications called antidepressants and has been prescribed to treat your depression.

Agomelatinais used in adults.

Depression is a continued alteration of mood that interferes with daily life. The symptoms of depression vary from person to person, but usually consist of a deep sadness, feelings of uselessness, loss of interest in hobbies, sleep disturbances, feeling of slowness, feeling of anxiety, and weight changes.

The expected benefits ofagomelatinaare to gradually reduce and eliminate the symptoms related to your depression.

Do not take agomelatine

-if you are allergic to agomelatine or any of the other ingredients of this medicine (listed in section 6).

-if your liver does not function properly (liver insufficiency).

-if you are taking fluvoxamine (another medicine used in the treatment of depression) or ciprofloxacin (an antibiotic).

Warnings and precautions

There may be reasons why agomelatine is not suitable for you:

-If you are taking medicines that are known to affect the liver. Ask your doctor about these medicines.

-If you have obesity or overweight, ask your doctor.

-If you are diabetic, ask your doctor.

-If you have elevated liver enzyme levels before treatment, your doctor will decide if this medicine is suitable for you.

-If you have bipolar disorder, have experienced or develop manic symptoms (a period of excessive excitement and abnormal elevation of emotions), inform your doctor before starting to take this medicine or before continuing to take it (see also “Possible side effects” in section 4).

-If you have dementia, your doctor will perform an individual assessment to decide if it is appropriate for you to take agomelatine.

During your treatment with agomelatine:

What to do to avoid potentially serious liver problems:

- Your doctor must check that your liver is functioning correctlybefore starting treatment.Some patients may experience increases in blood levels of liver enzymes during treatment with this medicine. Therefore, follow-up analyses should be performed with the following frequency:

Based on the evaluation of these analyses, your doctor will decide if you should receive or continue to use this medicine (see also section 3 “How to take agomelatine”).

Be aware of the signs and symptoms that may indicate that your liver is not functioning properly.

-If you noticeany of these signs and symptoms of liver problems:unusual darkening of urine, pale stools, yellowing of the skin/eyes, upper right abdominal pain, unusual fatigue (especially associated with other previously mentioned symptoms), seek urgent advice from a doctor, who may recommend stopping treatment with agomelatine.

The effect of agomelatine has not been documented in patients over 75 years. Agomelatine should therefore not be used in these patients.

Thoughts of suicide and worsening of depression

If you are depressed, you may occasionally have thoughts of self-harm or suicide. These thoughts may be increased at the beginning of treatment with antidepressants, as all these medicines take time to exert their effect, usually two weeks but sometimes longer.

It is more likely that you will have these thoughts:

-if you have previously had thoughts of self-harm or suicide.

-if you are a young adult. There is information from clinical trials that has shown an increased risk of suicidal behavior in young adults (under 25 years) who have a psychiatric disorder and are being treated with antidepressants.

Contact your doctor or go directly to the hospital as soon as you have any thoughts of self-harm or suicide.

It may be helpful to tell a close relative or friend that you are depressed and ask them to read this leaflet. You may ask them to tell you if they notice that your depression is worsening, or if they are concerned about changes in your behavior.

Children and adolescents

This medicine is not intended for use in children and adolescents (under 18 years).

Use of agomelatine with other medicines

Inform your doctor or pharmacist if you are using or have recently used or may need to take any other medicine.

You should not take agomelatine with certain medicines (see also “Do not take agomelatine” in section 2): fluvoxamine (another medicine used in the treatment of depression) and ciprofloxacin (an antibiotic) as they may modify the planned dose of agomelatine in your blood.

Make sure to inform your doctor if you are taking any of the following medicines: propranolol (a beta-blocker used in the treatment of hypertension), enoxacine (an antibiotic) and if you smoke more than 15 cigarettes per day.

Agomelatine and alcohol

It is not recommended to drink alcohol while being treated with this medicine.

Pregnancy

If you are pregnant or breastfeeding, consult your doctor or pharmacist before using this medicine.

Breastfeeding

Consult your doctor if you are breastfeeding your child or intend to do so, as you should stop breastfeeding if you take agomelatine.

Consult your doctor or pharmacist before using any medicine.

Driving and operating machinery

You may feel dizziness or drowsiness that may affect your ability to drive or operate machinery. Make sure you are sure of your reaction before driving or operating machinery.

Agomelatine Stada contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially “sodium-free”.

Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.

The recommended dose ofagomelatineis one tablet (25 mg) before bedtime. In some cases, your doctor may prescribe a higher dose (50 mg), that is, two tablets to be taken together before bedtime.

In most people with depressionagomelatinestarts to act on the symptoms of depression within a period of two weeks from the start of treatment. Your doctor may continue prescribing this medication when you feel better to prevent depression from coming back.

Your depression should be treated for a sufficient period of at least 6 months to ensure that you no longer have symptoms.

Do not stop taking your medication without consulting your doctor even if you feel better.

This medicationis for oral administration. You should swallow your tablet with the help of a glass of water. You can takeagomelatinewith or without food.

How to switch from an antidepressant (SSRI / SNRI) toagomelatine?

If your doctor changes your previous antidepressant medication from an SSRI or SNRI toagomelatine, they will inform you about how to discontinue treatment with your previous medication when you start takingagomelatine.

You may experience withdrawal symptoms related to the interruption of previous treatment for several weeks, even if the dose of your previous antidepressant medication is gradually reduced.

Withdrawal symptoms include: dizziness, numbness, sleep disturbance, agitation or anxiety, headache, nausea, vomiting, and tremors. These effects are generally mild to moderate and disappear spontaneously within a few days.

If treatment withagomelatinebegins while the dose of the previous medication is gradually reduced, possible withdrawal symptoms should not be confused with a lack of effect ofagomelatineat the beginning of treatment.

You should consult your doctor about the best way to discontinue your previous antidepressant treatment when you start treatment withagomelatine.

Liver function monitoring (see also section 2):

Your doctor will ask for tests to check that your liver is functioning properly before starting treatment and, subsequently, periodically during treatment, normally after 3 weeks, 6 weeks, 12 weeks, and 24 weeks. If your doctor increases the dose to 50 mg, tests should be performed at the time of dose increase and, subsequently, periodically during treatment, normally after 3 weeks, 6 weeks, 12 weeks, and 24 weeks. Subsequently, tests will be performed if the doctor considers it necessary.

You should not use this medicationif your liver is not functioning properly.

If you have kidney problems, your doctor will perform an individual evaluation to decide if it is safe for you to take this medication.

If you take moreagomelatinethan you should

In case of overdose or accidental ingestion, consult your doctor, pharmacist, or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.

The experience of overdose withagomelatineis limited, but the symptoms reported include upper stomach pain, drowsiness, fatigue, agitation, anxiety, tension, dizziness, cyanosis, or general discomfort.

If you forgot to take agomelatine

Do not take a double dose to compensate for the missed doses. Simply take the next dose at the usual time.

The printed calendar in the blister pack containing the tablets will help you remember when you last took a tablet ofagomelatine.

If you interrupt treatment withagomelatine

You should ask your doctor before interrupting treatment with this medication.

If you think the effect ofagomelatineis too strong or too weak, consult your doctor or pharmacist.

If you have any other doubts about the use of this medication, ask your doctor or pharmacist.

Like all medications, this medication may produce adverse effects, although not everyone will experience them.

The majority of adverse effects are mild or moderate. They usually appear in the first two weeks of treatment and are normally transient.

These adverse effects include:

- Very Common Adverse Effects (may affect more than 1 in 10 people): headache.

- Common Adverse Effects (may affect up to 1 in 10 people): dizziness, drowsiness, insomnia (difficulty sleeping), nausea, diarrhea, constipation, abdominal pain, back pain, fatigue, anxiety, abnormal dreams, elevated liver enzyme levels in the blood, vomiting, weight gain.

- Uncommon Adverse Effects (may affect up to 1 in 100 people): migraine, paresthesia (tingling in the fingers and toes), blurred vision, restless leg syndrome (a disorder characterized by an irresistible urge to move the legs), tinnitus (ringing in the ears), excessive sweating (hyperhidrosis), eczema, pruritus, urticaria (hives), agitation, irritability, restlessness, aggressive behavior, nightmares, mania/hypomania (see also "Warnings and Precautions" in section 2), suicidal thoughts or behavior, confusion, weight loss.

- Rare Adverse Effects (may affect up to 1 in 1,000 people): severe skin rash (erythematous rash), facial edema (swelling) and angioedema (swelling of the face, lips, tongue, and/or throat that may cause difficulty breathing or swallowing), hepatitis, jaundice (yellowing of the skin or eyes), liver failure*, hallucinations, inability to remain still (due to physical and mental restlessness), inability to completely empty the bladder.

* A reduced number of cases led to liver transplant or death.

Reporting Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect not listed in this prospectus. You can also report them directly through the national notification system: Spanish System for Pharmacovigilance of Medicinal Products for Human Use: https:// www.notificaRAM.es . By reporting adverse effects, you can contribute to providing more information on the safety of this medication.

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date that appears on the packaging and blister, after CAD. The expiration date is the last day of the month indicated.

Store in the original packaging to protect it from moisture. This medication does not require special storage conditions.

Medications should not be disposed of through drains or trash. Deposit the packaging and medications you no longer need at the SIGRE point of the pharmacy. Ask your pharmacist how to dispose of the packaging and medications you no longer need. In this way, you will help protect the environment.

Composition of Agomelatina Stada

• The active ingredient is agomelatine. Each film-coated tablet contains co-crystals of agomelatine-citric acid equivalent to 25 mg of agomelatine.
• The other components present in the core are colloidal silicon dioxide, microcrystalline cellulose, mannitol, povidone, anhydrous colloidal silica, crospovidone, sodium fumarate ester, magnesium stearate, and stearic acid.
• The coating components are hypromellose, macrogol, titanium dioxide (E171), talc, and yellow iron oxide (E172).

Appearance of Agomelatina Stada and content of the container

Agomelatina Stada 25 mg film-coated tablets are yellow, oblong, biconvex, measuring 9 mm x 4.5 mm.

Agomelatina Stada 25 mg film-coated tablets are available in blisters. The containers contain 7, 14, 28, 42, 56, 84, 98, or 100 (clinical pack) tablets or 7x1, 14x1, 28x1, 42x1, 56x1, 84x1, 98x1, 100 (clinical pack) x1 tablets (single dose).

Only some container sizes may be commercially marketed.

Holder of the marketing authorization and responsible for manufacturing

Holder of the Marketing Authorization

Laboratorio STADA, S.L.

Frederic Mompou, 5

08960 Sant Just Desvern (Barcelona)

Spain

[email protected]

Responsible for manufacturing

MEDIS International a.s., výrobní závod Bolatice

Prumyslova 961/16

747 23 Bolatice

Republic of Czech

or

STADA Arzneimittel AG

Stadastrasse 2 – 18

61118 Bad Vilbel

Germany

Last review date of this leaflet: July 2018

The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/.